Site Map
Posts
- Category: Wp Feeds (continued)
- Harvoni Tackles Uncommon HCV Variants (CME/CE)
- HAV Vaccinations Recommended for Homeless
- Having a Healthcare 'Navigator' Ups Cancer Screening (CME/CE)
- HBV Damage Disappears With Long-Term Therapy (CME/CE)
- HBV Drugs Cut Risk of Cancer Recurrence (CME/CE)
- HBV Immunotherapy Safe But Efficacy Lacking
- HBV Rebound Common for Some Patients (CME/CE)
- HBV Screening Hit or Miss in Rituximab Users
- HBV Tests Urged for High-Risk Groups
- HBV Therapy May Cut Liver Cancer Risk (CME/CE)
- HCV Admissions Rise While HIV Ones Fall (CME/CE)
- HCV Admissions Rise While HIV Ones Fall (CME/CE)
- HCV Admissions Rise While HIV Ones Fall (CME/CE)
- HCV Admissions Rise While HIV Ones Fall (CME/CE)
- HCV Admissions Rise While HIV Ones Fall (CME/CE)
- HCV Admissions Rise While HIV Ones Fall (CME/CE)
- HCV Admissions Rise While HIV Ones Fall (CME/CE)
- HCV Bright Future Needs Primary Care Docs
- HCV Cluster Sexually Transmitted (CME/CE)
- HCV Combo Drug Cures Nearly All Cases (CME/CE)
- HCV Combo Impresses, but Use Unlikely (CME/CE)
- HCV Combo Promising in Difficult Patients (CME/CE)
- HCV Combo Tx Shows Wide Efficacy (CME/CE)
- HCV Combo Works Without Old Standbys (CME/CE)
- HCV Drug Appears Safe in CKD (CME/CE)
- HCV Drug Combo Cures Most in Select Group (CME/CE)
- HCV Drug Combo Has Near-Perfect Response Rate
- HCV Drug Combo Promising All on Its Own (CME/CE)
- HCV Drug Combo Succeeds in Advanced Disease (CME/CE)
- HCV Drug Out of the Running
- HCV Drugs Costly but Cure Might Not Be (CME/CE)
- HCV Drugs Costly but Cure Might Not Be (CME/CE)
- HCV Genotype Test Kit OK'd
- HCV in Spotlight at Liver Meeting
- HCV Linked to Higher Cancer Risk (CME/CE)
- HCV on the Rise in Dialysis Patients, CDC Warns
- HCV Oral Combo Nearly Perfect
- HCV Patients Face Obstacles to Treatment
- HCV Patients May Be Able to Delay Therapy
- HCV Patients With Cirrhosis Respond Well to Combo Tx (CME/CE)
- HCV Prevalence Down Slightly
- HCV Rates High in Injecting Drug Users (CME/CE)
- HCV Regimen: No Interferon, No Ribavirin, No Problem (CME/CE)
- HCV Screen Based on Birth Cohort Proves Cost-Effective (CME/CE)
- HCV Screening Benefit Still Uncertain (CME/CE)
- HCV Studies Give Hope for Interferon-Free Therapy (CME/CE)
- HCV Test Might Alter Drug Abuse Behavior (CME/CE)
- HCV Therapy Response Tied to Survival (CME/CE)
- HCV Transmission a Problem in NAT-Negative Liver Donors (CME/CE)
- HCV Treatment Can Avert Transplant Even in Severe Disease
